2016, The pathobiology of MS involves a complex interplay of mechanisms that varies over time: Genes, Immune System, Environment. This presentation focuses on the role of genes.
- Genetic predisposition to MS (hereditary factors)
- Genetic factors and MS clinical course
- Genetic factors and effects of therapy of MS (DMT) – pharmacogenetics
- Possible mechanisms of the regulation of gene expression in MS
Prof Hans-Peter Hartung, MD, PhD, FRCP, is Professor and Chairman of the Department of Neurology at Heinrich-Heine University, Dusseldorf, Germany. Research Interest: Pathogenesis of autoimmune diseases of the central and peripheral nervous system (MS, GBS, CIDP) and their animal models and design and exploration of experimental therapies. Development of regenerative therapies for inflammatory, ischemic and traumatic insults to the nervous system. Development of new immunomodulatory therapies for MS, GBS, CIDP and identification of biomarkers of diease activity, prognosis, therapeutic response.
Alexei Boyko gained his MD and PhD from the Russian State Medical University, Moscow and has been Professor of the Department of Neurology and Neurosurgery at this university since 1997. He was the Chief Neurologist of the Department of Health Care of the Government of Moscow in 2001-2015, Director of the Moscow Multiple Sclerosis Center in 2004-2014 and Director of the MS Clinical and Research Center of Neuroclinic since 2015, Director of the Neuroimmunological Department of the Federal Center CVPS. Professor Boyko has been a member of the “Oslo International Think-tank on MS Epidemiology, Analytical Approaches to Study of the Aetiology” at the Center for Advanced Studies of the Norwegian Academy of Science and Letters in 1994-1995, and worked at UBC MS Center in 1998 (Vancouver, Canada).